Neuroendocrine Prostate Cancer Market Forecast Shows Accelerated CAGR Due to Diagnostic Advancements and Research Investment | DelveInsight
The neuroendocrine prostate cancer treatment space will experience significant changes during the forecast period of 2025–2034, owing to the launch of novel therapies such as BXCL701, Peluntamig, IMDELLTRA/IMDYLLTRA, PLUVICTO, FPI-2059, and others. However, the neuroendocrine prostate cancer market growth may also be impeded by factors such as treatment options in older age and dependency on blood transfusions.
New York, USA, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Neuroendocrine Prostate Cancer Market Forecast Shows Accelerated CAGR Due to Diagnostic Advancements and Research Investment | DelveInsight
The neuroendocrine prostate cancer treatment space will experience significant changes during the forecast period of 2025–2034, owing to the launch of novel therapies such as BXCL701, Peluntamig, IMDELLTRA/IMDYLLTRA, PLUVICTO, FPI-2059, and others. However, the neuroendocrine prostate cancer market growth may also be impeded by factors such as treatment options in older age and dependency on blood transfusions.
DelveInsight’s Neuroendocrine Prostate Cancer Market Insights report includes a comprehensive understanding of current treatment practices, emerging neuroendocrine prostate cancer drugs, market share of individual therapies, and current and forecasted neuroendocrine prostate cancer market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Key Takeaways from the Neuroendocrine Prostate Cancer Market Report
- According to DelveInsight’s analysis, the total neuroendocrine prostate cancer market size is expected to grow positively by 2034.
- The United States accounts for the largest market size of neuroendocrine prostate cancer, in comparison to EU4 (Germany, Italy, France, and Spain) and the UK, and Japan.
- In 2024, the US accounted for the highest prevalent cases of prostate cancer among the 7MM, i.e., 3.7 million.
- Prominent companies, including OnkosXcel Therapeutics (a Subsidiary of BioXcel Therapeutics), Phanes Therapeutics, Amgen, Novartis, Fusion Pharma, and others, are actively working on innovative neuroendocrine prostate cancer drugs.
- Some of the key neuroendocrine prostate cancer therapies in the pipeline include BXCL701, Peluntamig (PT217), IMDELLTRA/IMDYLLTRA (tarlatamab/AMG 757), PLUVICTO (lutetium Lu 177 vipivotide tetraxetan), FPI-2059, and others. These novel neuroendocrine prostate cancer therapies are anticipated to enter the neuroendocrine prostate cancer market in the forecast period and are expected to change the market.
Discover which neuroendocrine prostate cancer medications are expected to grab the market share @ Neuroendocrine Prostate Cancer Market Report
Neuroendocrine Prostate Cancer Market Dynamics
The neuroendocrine prostate cancer market dynamics are anticipated to change in the coming years. The increasing incidence of NEPC, coupled with growing disease awareness, governmental and organizational interest in patient health, and a lack of available treatments and competitors, is likely to drive the growth of the global treatment market by creating substantial opportunities for key players to develop and introduce effective novel and targeted therapies.
Furthermore, many potential therapies are being investigated for the treatment of neuroendocrine prostate cancer, and it is safe to predict that the treatment space will significantly impact the neuroendocrine prostate cancer market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate is expected to drive the growth of the neuroendocrine prostate cancer market in the 7MM.
However, several factors may impede the growth of the neuroendocrine prostate cancer market. The treatment landscape for NEPC is hindered by a low overall survival rate, high recurrence, poor patient prognosis, and multiple treatment challenges, compounded by the lack of approved drug therapies and the availability of alternative, generic, and off-label treatments that may hamper market growth.
Moreover, neuroendocrine prostate cancer treatment poses a significant economic burden and disrupts patients’ overall well-being and QOL. Furthermore, the neuroendocrine prostate cancer market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the neuroendocrine prostate cancer market growth.
Neuroendocrine Prostate Cancer Treatment Market
Platinum-based chemotherapy is frequently used in patients with pure small cell carcinoma, drawing on treatment strategies from small cell lung cancer (SCLC) and emerging evidence for Aggressive Variant Prostate Cancer (AVPC). This typically involves a regimen combining carboplatin (or occasionally cisplatin) with either etoposide (aligned with SCLC protocols) or a taxane, particularly when mixed histology or AVPC characteristics are present.
Beyond platinum therapies, treatment options for neuroendocrine prostate cancer remain undefined. Depending on clinical presentation and pathological findings, second-line regimens used for SCLC or therapies used in castration-resistant prostate cancer (CRPC) may be considered. Immune checkpoint inhibitors might offer potential, as suggested by SCLC data, such as the use of atezolizumab with platinum chemotherapy in the first-line setting, or nivolumab combined with ipilimumab as a second-line approach, but clinical studies specific to NEPC are lacking. At present, no drugs have received approval specifically for the treatment of NEPC.
Learn more about the neuroendocrine prostate cancer treatment options @ Neuroendocrine Prostate Cancer Treatment Guidelines
Neuroendocrine Prostate Cancer Emerging Drugs and Companies
The pipeline of NEPC is very robust, emerging therapies such as BXCL701 (OnkosXcel Therapeutics [a subsidiary of BioXcel Therapeutics]), Peluntamig (Phanes Therapeutics), IMDELLTRA/IMDYLLTRA (tarlatamab, Amgen), PLUVICTO (AAA617, Novartis), FPI-2059 (Fusion Pharma), and others are being developed for safe and efficacious treatments.
BXCL701 is an investigational oral agent designed to activate the innate immune system. In a Phase IIa clinical trial, it achieved a 25% composite response rate in patients with metastatic castration-resistant prostate cancer (mCRPC) exhibiting the small cell neuroendocrine carcinoma (SCNC) phenotype. The drug is currently under development as a potential treatment for aggressive prostate cancers and advanced solid tumors, particularly those that are resistant or unresponsive to checkpoint inhibitors.
In February 2024, BioXcel Therapeutics received Fast Track Designation from the FDA for BXCL701 when used in combination with a checkpoint inhibitor for SCNC patients who have progressed after chemotherapy and show no signs of microsatellite instability. Previously, in August 2023, development of BXCL701 was temporarily halted due to a strategic shift in company priorities.
PT217 is a novel bispecific antibody that targets both delta-like ligand 3 (DLL3) and CD47. It is currently being investigated in the ongoing multicenter Phase I/II SKYBRIDGE trial (NCT05652686), which includes dose-escalation and expansion cohorts. The study is evaluating PT217 as a monotherapy and in combination with TECENTRIQ (atezolizumab) in patients with advanced or treatment-resistant DLL3-expressing tumors, such as small cell lung cancer (SCLC), large cell neuroendocrine carcinoma (LCNEC), and extra-pulmonary neuroendocrine carcinoma (EP-NEC), including neuroendocrine prostate cancer (NEPC).
In August 2024, Phanes Therapeutics announced that the FDA had granted orphan drug designation (ODD) to PT217 for treating neuroendocrine carcinoma. Later, in December 2024, the FDA also granted Fast Track Designation (FTD) to PT217 for the treatment of patients with metastatic de novo or treatment-emergent NEPC.
The anticipated launch of these emerging neuroendocrine prostate cancer therapies are poised to transform the neuroendocrine prostate cancer market landscape in the coming years. As these cutting-edge neuroendocrine prostate cancer therapies continue to mature and gain regulatory approval, they are expected to reshape the neuroendocrine prostate cancer market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
To know more about new treatment for neuroendocrine prostate cancer, visit @ Neuroendocrine Prostate Cancer Management
Recent Developments in the Neuroendocrine Prostate Cancer Market
- In December 2024, the US FDA granted Fast Track Designation (FTD) to PT217 for the treatment of patients with metastatic de novo or treatment-emergent NEPC.
- In February 2024, BioXcel Therapeutics received Fast Track Designation from FDA for BXCL701 in combination with a CPI for the treatment of patients with metastatic for the treatment of SCNC with progression on chemotherapy and no evidence of microsatellite instability.
Neuroendocrine Prostate Cancer Overview
Neuroendocrine prostate cancer is a highly aggressive form of prostate cancer that can either develop independently or emerge in patients previously treated with hormonal therapy for prostate adenocarcinoma as a form of treatment resistance. Although identifying NEPC is clinically important, its defining features are not well established, which limits the ability to determine optimal timing for biopsy to detect histologic transformation.
Currently, NEPC is diagnosed through a biopsy of metastatic lesions, confirming the tumor’s morphology. While no standardized guidelines exist for when to perform such biopsies, they may be considered in patients exhibiting unusually aggressive disease, atypical metastatic patterns, or progression despite low or stable PSA levels. The NCCN guidelines suggest considering metastatic biopsy in suspected NEPC cases, as patients developing small cell carcinoma may benefit from platinum-based chemotherapy regimens, similar to those used in small cell lung cancer.
Neuroendocrine Prostate Cancer Epidemiology Segmentation
The neuroendocrine prostate cancer epidemiology section provides insights into the historical and current neuroendocrine prostate cancer patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.
The neuroendocrine prostate cancer market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
- Total Incident Cases of Prostate Cancer
- Total Incident Cases of NEPC
- Type-specific Cases of NEPC
- Treated Cases of NEPC
Download the report to understand which factors are driving neuroendocrine prostate cancer epidemiology trends @ Neuroendocrine Prostate Cancer Treatment Algorithm
| Neuroendocrine Prostate Cancer Report Metrics | Details |
| Study Period | 2020–2034 |
| Neuroendocrine Prostate Cancer Report Coverage | 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] |
| Key Neuroendocrine Prostate Cancer Companies | OnkosXcel Therapeutics (a Subsidiary of BioXcel Therapeutics), Phanes Therapeutics, Amgen, Novartis, Fusion Pharma, and others |
| Key Neuroendocrine Prostate Cancer Therapies | BXCL701, Peluntamig (PT217), IMDELLTRA/IMDYLLTRA (tarlatamab/AMG 757), PLUVICTO (lutetium Lu 177 vipivotide tetraxetan), FPI-2059, and others |
Scope of the Neuroendocrine Prostate Cancer Market Report
- Neuroendocrine Prostate Cancer Therapeutic Assessment: Neuroendocrine Prostate Cancer current marketed and emerging therapies
- Neuroendocrine Prostate Cancer Market Dynamics: Conjoint Analysis of Emerging Neuroendocrine Prostate Cancer Drugs
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Neuroendocrine Prostate Cancer Market Access and Reimbursement
Discover more about neuroendocrine prostate cancer drugs in development @ Neuroendocrine Prostate Cancer Clinical Trials
Table of Contents
| 1 | Key Insights |
| 2 | Report Introduction |
| 3 | Executive Summary |
| 4 | Key Events |
| 5 | Epidemiology and Market Methodology |
| 6 | NEPC: Market Overview at a Glance |
| 6.1 | Total Market Share (%) Distribution of NEPC by Therapies in 2024 |
| 6.2 | Total Market Share (%) Distribution of NEPC by Therapies in 2034 |
| 7 | Disease Background and Overview: NEPC |
| 7.1 | Introduction |
| 7.2 | Risk Factors |
| 7.3 | Symptoms |
| 7.4 | Pathophysiology and disease pathways |
| 7.5 | Diagnostic Tests: Biomarker assays |
| 8 | Treatment and Guidelines |
| 8.1 | Current Treatment Landscape |
| 9 | Epidemiology and Patient Population |
| 9.1 | Key Findings |
| 9.2 | Assumptions and Rationale |
| 9.3 | Total Incident Cases of NEPC in the 7MM |
| 9.4 | The United States |
| 9.4.1 | Total Incident Cases of Prostate Cancer in the United States (2020–2034) |
| 9.4.2 | Total Incident Cases of NEPC in the United States (2020–2034) |
| 9.4.3 | Type-specific Cases of NEPC in the United States (2020–2034) |
| 9.4.4 | Treated Cases of NEPC in the United States (2020–2034) |
| 9.5 | EU4 and the UK |
| 9.6 | Japan |
| 10 | Patient Journey |
| 11 | Emerging Therapies |
| 11.1 | Key Competitors |
| 11.2 | BXCL701: OnkosXcel Therapeutics (a Subsidiary of BioXcel Therapeutics) |
| 11.2.1 | Product Description |
| 11.2.2 | Other Developmental Activities |
| 11.2.3 | Clinical Development Activity |
| 11.2.3.1 | Clinical Trial Information |
| 11.2.4 | Safety and Efficacy |
| 11.2.5 | Analyst Views |
| 11.3 | PT217: Phanes Therapeutics |
| List to be continued in the report… | |
| 12 | NEPC: Market Size |
| 12.1 | Key Findings |
| 12.2 | Market Outlook |
| 12.3 | Conjoint Analysis |
| 12.4 | Key Market Forecast Assumptions |
| 12.4.1 | Cost Assumptions and Rebates |
| 12.4.2 | Pricing Trends |
| 12.4.3 | Analogue Assessment |
| 12.4.4 | Launch Year and Therapy Uptakes |
| 12.5 | Total Market Size of NEPC Cancer in the 7MM |
| 12.6 | The United States Market Size |
| 12.6.1 | Total Market Size of NEPC Cancer in the United States |
| 12.6.2 | Total Market Size of NEPC Cancer by Therapies in the United States |
| 12.7 | EU4 and the UK Market Size |
| 12.8 | Japan Market Size |
| 13 | Unmet Needs |
| 14 | SWOT Analysis |
| 15 | KOL Views |
| 16 | Market Access and Reimbursement |
| 17 | Bibliography |
| 18 | Report Methodology |
Related Reports
Prostate Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key prostate cancer companies including AstraZeneca, Arvinas, Madison Vaccines, Phosplatin Therapeutics, Hinova Pharmaceuticals, Bristol Myers Squibb, Merck, MacroGenics, Daiichi Sankyo, Seagen, Taiho Pharmaceutical, Modra Pharmaceuticals, Xencor, Point Biopharma, Lantheus Holdings, Zenith Epigenetics, Essa Pharma, Telix Pharmaceuticals, Kintor Pharmaceutical, AB Science, Eli Lilly and Company, Exelixis among others.
Prostate Cancer Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key prostate cancer companies, including Curium, Merck, Telix Pharmaceuticals, Exelixis, AstraZeneca, AB Science, Lantheus, Pfizer, Jiangsu Hengrui Pharmaceuticals, Modra Pharmaceuticals, Bristol-Myers Squibb, MacroGenics, Syntrix Pharmaceuticals, Zenith Epigenetics, Xencor, Bristol Myers Squibb, Merus, Phosplatin Therapeutics, Laekna Therapeutics, Tavanta Therapeutics, Madison Vaccines, Taiho Pharmaceutical, Kangpu Biopharmaceuticals, Arvinas, Candel Therapeutics, Blue Earth Therapeutics, Ipsen Biopharmaceuticals, LAVA Therapeutics, Essa Pharma, Poseida Therapeutics, Janux Therapeutics, Aurigene Oncology, Sathgen Therapeutics, Full-Life Technologies, NextPoint Therapeutics, AbbVie, SL VAXiGEN, Sorrento Therapeutics, Inc., 858 Therapeutics, Avacta Life Sciences Ltd, Nammi Therapeutics, BeiGene, DualityBio, among others.
Neuroendocrine Tumors Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key neuroendocrine tumors companies, including Merck, Progenics Pharmaceuticals, Lantheus Holdings, Fujifilm Toyama Chemical, Advanced Accelerator Applications S.A. (Novartis), FUJIFILM Toyama Chemical, Ipsen Biopharmaceuticals, Shionogi, Nippon Kayaku, Kyowa Hakko Kirin, Novartis, Pfizer, Bausch Health, Ono Pharmaceutical, ITM Solucin GmbH, Camurus, Ipsen, Takeda, Exelixis, BMS, RayzeBio, Radiomedix, Orano Med, Crinetics Pharmaceuticals, Chimerix, Perspective Therapeutics, Teclison, Chimeric Therapeutics, PharmaMar, Incyte Corporation, Enterome, Elicera Therapeutics, among others.
Metastatic Prostate Cancer Market
Metastatic Prostate Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key metastatic prostate cancer companies including AstraZeneca, Arvinas, Madison Vaccines, Phosplatin Therapeutics, Hinova Pharmaceuticals, Bristol Myers Squibb, Merck, MacroGenics, Daiichi Sankyo, Seagen, Taiho Pharmaceutical, Modra Pharmaceuticals, Xencor, Point Biopharma, Lantheus Holdings, Zenith Epigenetics, Essa Pharma, Telix Pharmaceuticals, Kintor Pharmaceutical, AB Science, Eli Lilly and Company, Exelixis among others.
Metastatic Castration-Resistant Prostate Cancer Market
Metastatic Castration-Resistant Prostate Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key mCRPC companies including AstraZeneca, Merck Sharp & Dohme, Hinova Pharmaceuticals, Pfizer, Astellas Pharma, Modra Pharmaceuticals, AB Science, Eli Lilly and Company, Zr Pharma & GmbH, Bristol-Myers Squibb, Ipsen, Exelixis, Takeda, Janssen Research & Development, Tesaro, Lantheus Holdings, Kintor Pharmaceutical, MacroGenics, Daiichi Sankyo, Madison Vaccines, Novartis, Point Biopharma, Xencor, Essa Pharma, Telix International, Bayer, Arvinas, among others.
DelveInsight’s Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion.
Other Business Pharmaceutical Consulting Services
Healthcare Conference Coverage
Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect with us on LinkedIn|Facebook|Twitter
Contact Us Shruti Thakur info@delveinsight.com +14699457679 www.delveinsight.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
